At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
FRNM Freenome, Inc.
Market Closed 09-11 16:00:00 EDT
14.37
-0.42
-2.84%
盘后14.65
+0.28+1.95%
19:30 EDT
High15.14Low14.37Vol538.46K
Open14.85D1 Closing14.79Amplitude5.19%
Mkt Cap1.54BTradable Cap984.02MTotal Shares107.00M
T/O7.85MT/O Rate0.79%Tradable Shares68.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Freenome Initiated at Buy by Guggenheim
Dow Jones  ·  08-20
Freenome Initiated at Buy by Guggenheim
Freenome, Inc. : Guggenheim Initiates Coverage with Buy Rating; Price Target $21
THOMSON REUTERS  ·  08-20
Freenome, Inc. : Guggenheim Initiates Coverage with Buy Rating; Price Target $21
Freenome initiated with a Buy at Guggenheim
TIPRANKS  ·  08-20
Freenome initiated with a Buy at Guggenheim
U.S. Research Roundup-Amgen, Analog Devices, Moderna
Reuters  ·  08-20
U.S. Research Roundup-Amgen, Analog Devices, Moderna
Freenome Registers Up To 75.2 Million Shares For Sale
MT Newswires Live  ·  08-19
Freenome Registers Up To 75.2 Million Shares For Sale
Freenome - Selling Securityholders May Offer up to 75,188,742 Shares of Common Stock - SEC Filing
THOMSON REUTERS  ·  08-19
Freenome - Selling Securityholders May Offer up to 75,188,742 Shares of Common Stock - SEC Filing
Freenome Shares Rise After Jefferies Initiates Coverage
MT Newswires Live  ·  08-18
Freenome Shares Rise After Jefferies Initiates Coverage
Correction: Jefferies Initiates Freenome at Buy, With $17 Price Target
MT Newswires Live  ·  08-17
Correction: Jefferies Initiates Freenome at Buy, With $17 Price Target
Freenome, Inc. : Btig Initiates Coverage with Buy Rating; Price Target $17
THOMSON REUTERS  ·  08-17
Freenome, Inc. : Btig Initiates Coverage with Buy Rating; Price Target $17
BTIG Initiates Freenome at Buy, With $17 Price Target
MT Newswires Live  ·  08-17
BTIG Initiates Freenome at Buy, With $17 Price Target
Jefferies Initiates Freenome at Hold, With $17 Price Target
MT Newswires Live  ·  08-17
Jefferies Initiates Freenome at Hold, With $17 Price Target
Freenome Price Target Announced at $17.00/Share by BTIG
Dow Jones  ·  08-17
Freenome Price Target Announced at $17.00/Share by BTIG
Freenome initiated with a Buy at Jefferies
TIPRANKS  ·  08-17
Freenome initiated with a Buy at Jefferies
Freenome Initiated at Outperform by Leerink Partners
Dow Jones  ·  08-15
Freenome Initiated at Outperform by Leerink Partners
Leerink Partners Capital Initiates Freenome With Outperform Rating, With $18 Price Target
MT Newswires Live  ·  08-14
Leerink Partners Capital Initiates Freenome With Outperform Rating, With $18 Price Target
Freenome Says It Has Obtained FDA Breakthrough Device Designation for Lung Cancer Screening Test
MT Newswires Live  ·  08-12
Freenome Says It Has Obtained FDA Breakthrough Device Designation for Lung Cancer Screening Test
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based Simplescreen™ Lung Cancer Screening Test
THOMSON REUTERS  ·  08-12
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based Simplescreen™ Lung Cancer Screening Test
Freenome, Abbott Laboratories' Colorectal Cancer Screening Test Approved by FDA; Freenome Earns $100 Million Milestone Payment
MT Newswires Live  ·  07-27
Freenome, Abbott Laboratories' Colorectal Cancer Screening Test Approved by FDA; Freenome Earns $100 Million Milestone Payment
Freenome, Abbott announce FDA approval of SimpleScreen CRC
TIPRANKS  ·  07-27
Freenome, Abbott announce FDA approval of SimpleScreen CRC
FDA Approves Freenome’s Simplescreen™ Crc Blood-Based Screening Test; Abbott to Commercialize in the U.S.
THOMSON REUTERS  ·  07-27
FDA Approves Freenome’s Simplescreen™ Crc Blood-Based Screening Test; Abbott to Commercialize in the U.S.
No data available

Introduction

Company Name.
Freenome, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Freenome, Inc. was incorporated in the Cayman Islands on March 22, 2024, and reincorporated in Delaware on July 21, 2026. The company is a development-stage early cancer detection company dedicated to developing blood-based screening tests that leverage its proprietary AI and machine learning multi-omics technology platform to transform the detection of multiple cancers and ultimately various diseases. The company is developing a portfolio of blood-based cancer screening tests, including its lead product for which a premarket approval application has been submitted to the FDA, an improved version, and a blood-based lung cancer detection test. Freenome has also initiated a clinical study to support the regulatory submission for its lung cancer detection test.
Issue price:
--